Neuro-Oncology n J U LY 2 0 0 1 201 Gene therapy using viral vectors has to date failed to reveal its de nitive clinical usefulness. Cell encapsulation technology represents an alternative, nonviral approach for the delivery of biologically active compounds to tumors. This strategy involves the use of genetically engineered producer cells that secrete a protein with therapeutic potential. The cells are encapsulated in an immunoisolating material that makes them suitable for transplantation. The capsules, or bioreactors, permit the release of recombinant proteins that may assert their effects in the tumor microenvironment. During the last decades, there has been signi cant progress in the development of encapsulation technologies that comprise devices for both macro-and microencapsulation. The polysaccharide alginate is the most commonly used material for cell encapsulation and is well tolerated by various tissues. A wide spectrum of cells and tissues has been encapsulated and implanted, both in animals and humans, indicating the general applicability of this approach for both research and medical purposes, including CNS malignancies. Gliomas most frequently recur at the resection site. To provide local and sustained drug delivery, the bioreactors can be implanted in the brain parenchyma or in the ventricular system. The development of comprehensive analyses of geno-and phenotypic pro les of a tumor (genomics and proteomics) may provide new and important guidelines for choosing the optimal combination of bioreactors and recombinant proteins for therapeutic use. Neuro-Oncology 3, 201-210, 2001 (Posted to Neuro-Oncology [serial online], Doc. 00-064,
S
ince the rst human gene therapy trial was initiated in 1990, an increasing number of viral gene therapy strategies have been developed targeting different malignancies (Marcel and Grausz, 1996) . Even though new viral treatment strategies may have unique application areas, gene therapy has at present failed to demonstrate its de nitive clinical usefulness (Puumalainen et al., 1998; Harsh et al., 2000; Warnick, 2000) . Major obstacles include a limited distribution of viruses (Lang et al., 2000) , low transfection ef cacy (Oyvind et al., 1999; Sandmair et al., 1999) , and a lack of viral speci city toward the tumor cells. An alternative strategy, used in our laboratory, involves the utilization of genetically engineered cells that secrete recombinant proteins that may interact with the tumor microenvironment (Read et al., 1999 (Read et al., , 2001 Thorsen et al., 2000) . To implant the cells, they are encapsulated in an immunoisolating substance, resulting in the formation of a bioreactor. Over the last decade, there has been substantial progress in the development of encapsulation technologies for allogeneic tissue and organ transplantation (Kühtreiber et al., 1999) . This article provides an overview of different encapsulation strategies, both in preclinical and clinical use, with an emphasis on the methods for microencapsulation of cells that secrete recombinant proteins that may affect the growth of CNS malignancies.
Immunoisolation Technology
The rst immunoisolation experiments were initiated as early as the 1930s (Biseeglie, 1933) , but serious scienti c interest in such technology developed in the 1970s with the encapsulation of pancreatic tissue into synthetic membranes (Chick et al., 1977; Tze and Chen, 1977) . In principle, the current encapsulation systems comprise a matrix with a porous membrane. The pore size usually ranges from 5 to 200 nm (Martinsen et al., 1992) and ideally allows the free exchange of nutrients, oxygen, and biotherapeutic substances, whereas immunocompetent cells are excluded (Kulseng et al., 1997) . The encapsulation systems comprise devices for macro-and microencapsulation. In macrocapsules, cells or tissues such as pancreatic islets can be implanted into diffusion chambers that function as arteriovenous shunts (Lanza et al., 1996) . In such devices, the blood ows through the lumen of a synthetic blood vessel, with the cells localized outside the fiber. Another approach for macroencapsulation is the use of synthetic hollow bers that are composed of tubular-shaped structures of thermoplastic material surrounding free or matrixbound cells (Renken and Hunkeler, 1998) .
Macroencapsulation devices can be retrieved fairly easily and, in the case of the hollow bers, the implantation only requires minimal invasive procedures . However, only a limited number of cells can be accommodated in these encapsulation systems, and the surface-to-volume ratio is unfavorable (Lanza et al., 1996) . In the treatment of diabetes, several meters of hollow bers are required for the implantation of sufcient pancreatic tissue to control the blood glucose level (Lacy, 1995) . Another disadvantage of the macrocapsules is membrane breakage. In addition, the arteriovenous shunts are prone to blood clotting (Renken and Hunkeler, 1998) .
Microcapsules have many advantages when compared with macrocapsules, including simplicity of fabrication; ease of implantation; a larger surface-to-volume ratio and cell fraction-to-volume ratio; and a wider specter of biomedical applications. In 1980, Lim and Sun reported the rst successful implantation of microencapsulated tissue (Lim and Sun, 1980) . They made a micro bio-organ by encapsulating islets of Langerhans in calcium alginate. After implantation in insulin-de cient rats, normoglycemia was achieved for 2 to 3 weeks. More recently, different polymers have been exploited for immunoisolation. A thorough screening of polymers for cytotoxic and cell attachment properties was performed by Wang et al. (1997) . Alginate had the lowest cytotoxicity and the best cell-attachment qualities, but carboxy methylcellulose, carrageenan, and hyaluronic acid (hyaluronan) were also good candidates for microencapsulation. Alternatively, cells can be attached to the surface of small microspheres made of glass, plastics, or polysaccharides such as collagen-coated gelatin beads (Cherksey et al., 1996) .
Despite the development of new polymers, Sun's classical alginate/calcium chloride capsule has been, and still is, the most important encapsulation biomaterial. The main reason for this is that animal studies and recent clinical trials suggest that alginate can provide long-term stability, biocompatibility, and viability of the transplanted cells (Laham et al., 1999; Soon-Shiong et al., 1994; Wu et al., 1989) .
Alginate
Alginates are natural polysaccharides that can be isolated from brown seaweed where they represent the extracellular matrix of the organism. These compounds have had commercial applications for decades, especially in the food industry where they are used as stabilizers and thickeners, and in the pharmaceutical industry for the treatment of wounds and esophageal re ux and as sustained drug-release systems (Onsøyen, 1996) . The alginate polymers consist of 2 linked anionic monomers, G and M. The polymer structure is composed of homopolymeric regions of G units (G blocks) and M units 3 (M blocks), interspersed with regions of mixed monomers (MG blocks). Alginate forms a gel in the presence of divalent cations, such as Ca 2+ , which link speci cally to the G blocks by binding to the free carboxyl groups. A schematic model of the gel network is referred to as the egg-box model (Grant et al., 1973; Morris et al., 1978) (Fig. 1A) . The M component is not important for the cross-linking of the alginate gel, and its contribution to the gel is not so well characterized. However, the M component has immunogenic properties (Otterlei et al, 1991; Kulseng et al., 1999) and it may evoke immune reactions when it is present at high concentrations (more than 85%) in the alginate. The mechanical stability of the alginate beads is critical in the physiologic environment where divalent ions, which are involved in the network formation, are exchanged with sodium ions of the body. This results in a loosening of the G-G bonds, with a subsequent increase in porosity, swelling of the capsule, and release of the biomaterial (Thu et al., 1996a) . The mechanical strength of the capsule can be raised by increasing the G content and the length of the G blocks in the alginate (Thu et al., 1996a) . A second method to improve the mechanical stability is to add an outer layer of polypeptides such as poly-L-lysine (Thu et al., 1996b) . Direct contact between the cytotoxic poly-L-lysine and the microenvironment can be prevented by applying an additional layer of alginate to cover the poly-Llysine/alginate capsule. The af nity of alginate for different divalent cations decreases in the following order: Cd>Ba>Sr>Ca>Ni>Cu>Mn. Barium is commonly used to increase the mechanical stability, and experiments have shown that even low molar concentrations of barium in the gelling solution can substantially decrease the capsule swelling (Peirone et al., 1998; Zekorn et al., 1992) . A higher mechanical stability can also be achieved by making inhomogeneous capsules. The homogeneity of the beads refers to whether the alginate is uniformly distributed throughout the capsule or whether it is concentrated in the outer part with a central cell-containing core (Fig. 1) . Inhomogeneous capsules can be prepared by removing the sodium ions or by adding an osmolyte, such as mannitol, to the gelling bath (Skjak-Braek et al., 1989) . Alternatively, serum proteins or medically approved per uorocarbons can be incorporated into the gel network (Hillgärtner et al., 1999) .
A variety of techniques can be used for the preparation of alginate microcapsules (Kühtreiber et al., 1999) , ranging from simple handmade beads where the alginate-cell suspension is dripped into the gelling bath via a syringe, to coaxial air jet or electrostatic bead generators. Some of these devices are now commercially available (http://www.nisco.ch/). In our experiments, we have used handmade microcapsules with a coaxial airstream system for size regulation (Read et al., 1999; Thorsen et al., 2000) or an electrostatic bead generator (Figs. 1, 2, and 3). The bead generator allows the production of thousands of beads per minute with a narrow size distribution. In addition, the set-up can be standardized and the size of the beads is easily adjusted by adjusting the voltage. A typical microcapsule measures 500 to 800 µm in diameter, although the bead generator allows the production of microcapsules as small as 200 µm in diameter.
Surgical Procedures
Transplantation of xenogeneic cells into the CNS involves different procedures that are adapted to the type of device to be implanted and the nature of the disease to be treated. In principle, they can be grouped into 2 categories, depending on whether the cells are implanted into the subarachnoid space or the brain parenchyma. From the subarachnoid space, biodistribution of neuroactive substances is mediated by CSF ow. This ow is directed from the production site in the choroid plexus of the ventricles to the arachnoid villi, where the uid is ltrated over to the blood circulation. Transplanting the producer cells to this location can be accomplished by performing lumbar puncture, which is less invasive than methods for depositing cells in the brain parenchyma, such as craniotomy or stereotactic surgery. The risk associated with narcosis is avoided by using lumbar puncture or a stereotactic technique. Lumbar puncture can be easily performed in most instances, but is contraindicated in patients with increased intracranial pressure from an intracranial expansion. This method has been applied by Aebischer and colleagues to treat patients with chronic pain or amyotrophic lateral sclerosis, using encapsulated cells releasing catecholamines and CNTF, respectively Buchser et al., 1996) . In both trials, they used a device comprising a 5-cm-long hollow ber membrane containing cells in a matrix and a silicon tether. The device was inserted at the L4-L5 level under local anesthesia using a Touhy needle, guide wire, and cannula. The active part, containing the producer cells, was thus situated in the CSF among the nerve roots of the cauda equina, whereas the silicone tether was sutured to the lumbodorsal fascia. In both trials, the implants were generally well tolerated, and the patients did not receive any immunosuppression. For other diseases, the treatment strategy will rely on local delivery, where the active substance is released in the vicinity of the target area. For diseases or lesions with a subcortical location, this involves intracerebral implantation. High local concentrations of the active substance can be provided with these systems and may be advantageous for conditions such as gliomas and Parkinson's disease. For gliomas, encapsulation devices can be implanted in the walls of the resection cavity after surgery. Transplanting cells to deep-seated areas, as in Parkinson's disease, requires a stereotactic surgical technique for optimal precision and minimal damage of nervous tissue. Even with less invasive techniques, all intracerebral implantation procedures will result in some destruction of vital tissue, and care must be taken to avoid the eloquent areas. Because intracerebral implantation involves direct contact between the brain tissue and the encapsulation device, a low immunogeneity of the implant is a fundamental premise.
Biocompatibility
Despite promising results reported in several animal experiments, limited graft survival may occur. This is attributed to host immune reactions against the implant. Zekorn et al. (1996) suggested 3 components to be considered in the evaluation of the biocompatibility of immunoisolating devices: the reaction of the encapsulated cells to the polymer and the method of encapsulation; the reaction of the recipient to the device (foreign body reaction); and the reaction of the recipient to the encapsulated cells and therapeutic product.
Reaction of the Encapsulated Cells to the Polymer
Successful encapsulation of bacteria, eucaryotic cells, and tissues such as islets of Langerhans has been achieved. Producer cell lines, for the treatment of experimental gliomas, show a high viability (60%-90%) and maintain the secretion of the recombinant proteins for weeks after encapsulation in alginate (Read et al., 1999 (Read et al., , 2001 . Although the cells are immobilized by the matrix, they have a high proliferative activity (Peirone et al., 1998) . The changes observed over time in the microcapsules emerge in 3 phases (Fig. 2) . In phase 1, the lag phase, a modest cell proliferation occurs as the cells adapt to the new microenvironment. The following 2 to 3 weeks, phase 2 of the process, involve proliferation of cells and the formation of the rst spheroids. Only cells that are able to form spheroids appear to survive. In phase 3, a steady state is established between cell proliferation and cell loss, which is con ned to the spheroids.
Reaction of the Recipient Toward the Beads
Several reports have described how graft survival is signicantly enhanced by encapsulation (Hasse et al., 1994 ; Lanza et al., 1995; Soon-Shiong et al., 1992) . However, microcapsule graft failure is often associated with brotic overgrowth of the capsules. As previously mentioned, a foreign body reaction has been attributed to the M component of the alginate, as the M family has strong immunogenic properties. For cell encapsulation and transplantation purposes, an alginate composition with less than 35% of M is considered to be most suitable (Jahr et al., 1997; Otterlei et al., 1991) and elicits only weak immune reactions in the brain (Read et al., 1999) . Recent reports however, suggest that the purity of the alginate is the vital factor for successful grafting (Hasse et al., 1998; van Schilfgaarde and de Vos, 1999) . Commercial alginates (not ultrapuri ed) have been shown to contain 20 to 30 mitogenic impurities that can elicit broblast activation . G-rich (M-poor) and ultrapure/amitogenic alginate, with a controllable level of pyrogeneity (endotoxin levels below 4 U), is at present commercially available (http://www. pronovabiomedical.com/).
Reaction of the Recipient Against the Encapsulated Cells
Immunoisolating devices prevent monocytes and lymphocytes from destroying the encapsulated producer cells, but immune reactions against the implant are not totally abolished. Several cases report that the host produces immunoglobulins against the encapsulated material as well as the secreted recombinant proteins (Hortelano et al., 1996; Siebers et al., 1999) . The host's tolerance to xenografts of encapsulated biomaterial also appears to vary between species (Weber et al., 1995) . Therefore, if speci c microcapsules are well tolerated in small animals, testing in large animal models is a prerequisite before clinical application.
The location of the implant may be important to circumvent the host's immune response. The CNS may actually represent a suitable site for implantation because of its speci c immunologic status. The immune responses in the CNS are mainly cellular, and the alginate provides a barrier against cell-mediated (lymphocytes, natural killer cells, or microglia) destruction of the producer cells. Because the idea of using microcapsules for the treatment of diseases in the CNS is novel, only limited information is available on the parenchymal reaction to the microcapsules. The alginates, with or without encapsulated producer cells, could theoretically elicit a brisk glial reaction that could abolish any therapeutic bene ts. To date, no clinical trials have been performed on this issue. There is also limited information available on alginate toxicity/reactivity in the brain in large animal models. However, Read et al. (1999) have studied the immunologic responses evoked in the rat brain upon implantation of microcapsules containing 293 producer cells. Tissue sections were stained for microglia (OX42), rat macrophages, T cells, and B cells after 1, 3, and 9 weeks. A limited accumulation of mononuclear cells was observed in the parenchyma adjacent to the microcapsules after 1 week, consisting mainly of microglia and macrophages. The immune reactivity decreased during the following weeks, and the morphology of the tissue in 
Biodistribution
Several studies have reported the delivery of recombinant gene products to the CNS. Ross and colleagues (1999) used alginate beads with mouse myoblasts releasing hGH and implanted these into the right lateral ventricle of mice. In vitro analyses indicated a relative stable secretion of hGH per volume of capsules for up to 75 days postencapsulation. Quanti cation of hGH by a solidphase enzyme-linked immunosorbent assay was performed on homogenized tissue from several regions from both hemispheres of the brain. Signi cant levels were detected up to 16 weeks after implantation with a peak at 8 weeks. Highest levels were measured in brain tissue from the implantation site and in the region anterior to it, suggesting a CSF-mediated spread. In addition, the distribution of hGH was assessed using immunocytochemistry. The protein was observed in a decreasing gradient from the implantation site within an area 1.5 to 2 mm in diameter. Fluorescence was also detected adjacent to the left ventricle, indicating that hGH released in the ventricular space had diffused into the surrounding parenchyma.
Thorsen and colleagues (2000) studied antibody release from encapsulated hybridoma cells. In vitro release from 10 beads, each containing 1.5 ´10 3 cells, was 13 ng/(ml/h) at the day of encapsulation, increasing steadily to a peak of 457 ng/(ml/h) at 12 days. During the last 3 weeks of the observation period, the production stabilized at 400 ng/(ml/h). After implantation in the rat brain, immunoglobulins could be observed at a distance of 1 mm from the implantation site of the alginate beads. Two of the rat brains displayed antibodies in the whole hemisphere, at the side of the implantation, and also in the leptomeninges of both hemispheres. Read et al. (2001) implemented the alginate concept in a therapeutic model where rats with brain tumors were treated with alginate beads containing human 293 cells releasing endostatin. In vitro, 10 beads released 2 µg/ml endostatin during a 48-h period. In vivo, release was veri ed by immunocytochemistry, which showed staining in the tumor tissue as well as by Western blot analysis of CSF samples. The prolonged survival observed in the intervention group suggests that the biodistribution is also signi cant for therapeutic applications (Read et al., 2001) .
In humans, the only source to date on biodistribution is from studies on intrathecal delivery from macroencapsulated cells. In a series of 6 patients with amyotrophic lateral sclerosis, Aebischer et al. (1996) implanted polymer capsules releasing CNTF into the lumbar space. Nanogram levels of CNTF were measured in patients' CSF for at least 17 weeks posttransplantation, whereas it was undetectable before implantation. In another study performed by Buchser et al. (1996) , patients with chronic pain were implanted with similar polymers with chromaf n cells releasing catecholamines with a strong analgesic effect. Even though the increase in CSF concentrations of the substance was not signi cant in the lumbar puncture aspirates, all patients using epidural morphine decreased the intake after implantation. Capsules retrieved from some of the patients several months after implantation still showed release of catecholamines, although it had decreased from the preimplant values. From these ndings, it can be concluded that the biodistribution of a recombinant protein can be maintained at a stable level for several months.
Whereas spreading within the CSF is mediated by bulk ow, distribution within the brain tissue or from CSF into brain tissue occurs by diffusion. However, some fundamental aspects concerning the nature of these processes should be noted: First, the spread of a biologically active substance by CSF ow is directional from the choroid plexus of the lateral ventricles to the subarachnoid space surrounding the brain and the spinal cord. Thus, at least for some neurologic diseases, the site of release should be upstream to the target area.
Second, diffusion is a slow process, and the time required to move a distance by diffusion is proportional to the square of the distance. Also, the substance released from the producer cells will have an exponentially declining concentration away from the beads. Therefore, an extensive in ltration of the target volume with the implants releasing the active substance will be required to reach therapeutic levels of the compound, especially for substances with a short half life.
Animal Experiments and Clinical Trials
Macrocapsules as well as microcapsules have been applied in a variety of animal models in vivo, and the number of clinical trials is also increasing (Tables 1 and  2 ). Several investigators have reported alleviations of symptoms of experimental parkinsonism in rats by implanting different devices with dopamine-releasing cells (Aebischer et al., 1991; Lindner et al., 1997) . In a monkey model of Huntington's diseases, CNTF released from encapsulated baby hamster kidney cells reduced the extent of striatal damage . Neural growth factors released from encapsulated cells have also been shown to slow down degeneration of motor neurons in different rodent models of amyotrophic lateral sclerosis (Sendtner et al., 1992) and to promote survival of axotomized septal cholinergic neurons (Winn et al., 1994) .
The experience and results achieved from animal experiments have provided a scienti c basis for several clinical trials. Soon-Shiong et al. (1994) implanted encapsulated islets intraperitoneally in a diabetic patient and detected insulin independence after 9 months. Others have applied encapsulated cells, installed intra-arterially, for the treatment of patients with advanced-stage pancreatic carcinoma (Løhr et al., 1999) .
Intrathecal delivery from macroencapsulated cells, as reported in patients with amyotrophic lateral sclerosis and chronic pain, demonstrates the potential for treating other CNS diseases using this technology. A clinical protocol for the enrollment of patients with Huntington's disease into a treatment with encapsulated CNTF-releasing cells has been recently published (Bachoud-Levi et al., 2000) . This treatment includes the implantation of 2.5-cm-long implants into the ventricles.
As previously described, Thorsen et al. (2000) showed that alginate beads provide a potent local delivery system of recombinant proteins to the brain, and they proposed this as a strategy for the treatment of cerebral malignancies. Since neovascularization is a hallmark of malignant gliomas and a prerequisite for neoplastic growth, angiogenesis inhibitors may suppress tumor growth by abolishing an adequate blood supply. This approach was used by Read and colleagues (2001) , who reported that rats with brain tumors implanted with endostatin-releasing beads lived signi cantly longer than untreated controls. Sectioning of the brains from treated animals revealed reduced vessel density and large necrotic areas in the vicinity of the beads; these changes were absent in the controls. Others have made similar ndings, reporting inhibition of subcutaneous glioblastoma xenografts from endostatin-releasing encapsulated cells (Joki et al., 2001) .
Applications of biodegradable polymers have also demonstrated an interstitial distribution of biologically active substances, and a therapeutic potential of local delivery systems has been demonstrated both in preclinical and clinical trials (Brem et al., 1995; Fung et al., 1998; Tamargo et al., 1993; Valtonen et al., 1997) . Incorporation of cytotoxic drugs into biodegradable polymers provides a sustained release of chemotherapeutic agents in the resection cavity, thereby obtaining a prolonged high exposure to remnant tumor tissue. Prospective, randomized, placebo-controlled trials have shown longer survival when carmustine-loaded polymers were used as an initial treatment for malignant gliomas (Valtonen et al., 1997) or for patients with recurrent gliomas (Brem et al., 1995) . Encapsulated cells, however, still have not been applied in any trial that included patients with malignant gliomas. Despite the lack of clinical data, this technology has certain unique characteristics that make it an attractive candidate for the treatment of glioma patients. The continuous production of the active substance by producer cells may provide high local tissue concentrations, even of substances with a short biological half life (Read et al., 2001) . Also, gene expression in the producer cells can be regulated using regulatory elements, such as a tetracycline-responsive element. This system can reversibly down regulate gene expression in a differentiated manner, as well as turn it off completely (Gossen and Bujard, 1992) .
Because most patients who have operations for glioblastomas subsequently undergo radiation therapy, encapsulated cells cannot be implanted during primary surgery. Initial trials should, for this reason, only include patients who are scheduled for re-operation due to the local recurrences or patients who have undergone radiation therapy prior to the primary operation. The encouraging data from animal experiments mentioned above give realistic hope that trials using cell encapsulation technology for patients with malignant gliomas can be started in the near future.
Future Prospects
The sequencing of the human genome is nearly completed, bringing research into the postgenomic area. In this context, cell encapsulation technology may provide us with a very potent tool to translate new knowledge into novel therapeutic strategies. On the basis of tumor biopsies from a patient, treatment may be individually tailored using genetically engineered cells that release active substances tted to the biological pro le of the tumor. This offers unique opportunities for combined regimens targeting all of the different aspects of tumor growth, such as proliferation, invasion, migration, and angiogenesis. Treatment centers can then access a "freeze-library" containing a variety of differently programmed cell lines and select those expressing the appropriate gene products (Fig. 3) . The challenge will then be to master the combined use of a high number of biologically active substances in a clinical setting. When these factors are brought into play with a force and synchronicity exceeding that of the brain tumor itself, progress will be made.
